Slide 1: RSV Older Adults Briefing Document
Investor Relations Briefing Note RSV Older Adults Briefing Document Phase III Overview Respiratory Syncytial Virus (RSV) Scientific innovation has led to significant recent advances in vaccine development for RSV. In a is one of the major remaining large pivotal phase III trial, our RSV OA vaccine i
Slide 2: The challenge of protecting older adults
RSV Older Adults Briefing Document The challenge of protecting older adults Older adults, as a cohort, is a very large and growing Older adults and comorbidities population. In the US alone, there are an estimated In adults, the highest burden of RSV disease is in those 70 million people aged 60 plu
Slide 3: The virus, how it works, and our vaccine technology
RSV Older Adults Briefing Document The virus, how it works, and our vaccine technology Vaccination offers a solution to RSV, Older adults are less responsive to to help improve health outcomes and vaccination due to age-related decline reduce healthcare costs. Only recently in immunity, specifically
Slide 4: The AReSVi-006 trial
RSV Older Adults Briefing Document The AReSVi-006 trial Around In June 2022, GSK became the first company to announce positive pivotal phase III results for an have been enrolled in the 25,000 RSV vaccine. Results of the pivotal phase III AReSVi-006 trial show trial from across patients our RSV OA v
Slide 5: Consistent high vaccine efficacy across a range of endpoints
RSV Older Adults Briefing Document Consistent high vaccine efficacy across a range of endpoints 94.1% 94.6% 93.8% Reduction Efficacy in Efficacy in in severe adults with adults aged RSV-LRTD underlying 70-79 years comorbidities Consistent efficacy across both RSV A and RSV B. In general, the vaccine
Slide 6: Additional GSK RSV older adult trials and supporting evidence
RSV Older Adults Briefing Document Additional GSK RSV older adult trials and supporting evidence AReSVi-006 is part of a comprehensive RSV evidence generation programme being conducted by GSK. Alongside it, we have additional trials and data as part of our comprehensive evidence generation plan: Tri
Slide 7: Overview of trials testing efficacy of RSV vaccines in older adults
RSV Older Adults Briefing Document Overview of trials testing efficacy of RSV vaccines in older adults The development of RSV vaccine candidates in the adult setting is evolving rapidly. Different technology platforms eliciting different mechanisms of action are being developed by several companies
Slide 8: Overview of trials testing efficacy of RSV vaccines in older adults (continued)
RSV Older Adults Briefing Document Overview of trials testing efficacy of RSV vaccines in older adults (continued) Company, Asset and technology Trial name (population) Phase Design and primary efficacy endpoint(s) Status Janssen/JNJ – JNJ-64400141 CYPRESS (Adults ≥65 yo) IIb Study to demonstrate th
Slide 9: Analyst and Investor enquiries
Analyst and Investor enquiries London Philadelphia Nick Stone Jeff McLaughlin nick.j.stone@gsk.com jeffrey.r.mclaughlin@gsk.com +44 (0) 7717 618834 +1 215 751 7002 James Dodwell Frannie DeFranco james.x.dodwell@gsk.com frances.p.defranco@gsk.com +44 (0) 20 8047 2406 +1 215 751 4855 Mick Readey Group